USA - engelsk - NLM (National Library of Medicine)

atlantic biologicals corps - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - phenobarbital 16.2 mg in 5 ml - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the following indications as “possibly” effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic megacolon; myasthenia gravis; hiatal hernia

USA - engelsk - NLM (National Library of Medicine)

unit dose services - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 16.2 mg in 5 ml

USA - engelsk - NLM (National Library of Medicine)

pbm pharmaceuticals inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - phenobarbital 16.2 mg in 5 ml - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the following indications as “possibly” effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic megacolon; myasthenia gravis; hiatal hernia

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 16.2 mg

USA - engelsk - NLM (National Library of Medicine)

pbm pharmaceuticals inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the following indications as “possibly” effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic megacolon; myasthenia gravis; hiatal hernia

USA - engelsk - NLM (National Library of Medicine)

pbm pharmaceuticals inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the following indications as “possibly” effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic megacolon; myasthenia gravis; hiatal hernia

USA - engelsk - NLM (National Library of Medicine)

pbm pharmaceuticals inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the following indications as “possibly” effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic megacolon; myasthenia gravis; hiatal hernia

USA - engelsk - NLM (National Library of Medicine)

carilion materials management - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - based on a review of this drug by the national academy of sciences-national research council and/or other information, fda has classified the following indications as “possibly” effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic mega-colon; myasthenia gravis; hiatal hernia

USA - engelsk - NLM (National Library of Medicine)

seton pharmaceuticals llc - .beta.-carotene (unii: 01yae03m7j) (.beta.-carotene - unii:01yae03m7j) - .beta.-carotene 2000 [iu]

USA - engelsk - NLM (National Library of Medicine)

major pharmaceuticals - vitamin a acetate (unii: 3le3d9d6oy) (vitamin a - unii:81g40h8b0t) - vitamin a 3080 [iu]